+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Cystic Fibrosis - Pipeline Review, H2 2019

  • ID: 4861730
  • Drug Pipelines
  • November 2019
  • Region: Global
  • 489 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • AbbVie Inc
  • Celtaxsys Inc
  • Evaxion Biotech ApS
  • Kither Biotech Srl
  • OrPro Therapeutics Inc
  • Sequoia Sciences Inc
  • MORE
Cystic Fibrosis - Pipeline Review, H2 2019

Summary

The Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Cystic Fibrosis - Pipeline Review, H2 2019, provides an overview of the Cystic Fibrosis (Respiratory) pipeline landscape.

Cystic fibrosis (CF) is an inherited disease that causes mucus to build up and clog some of the body’s organs, particularly the lungs and pancreas. Cystic fibrosis affects the cells that produce mucus, sweat and digestive juices. Symptoms include wheezing, breathlessness, repeated lung infections, inflamed nasal passages or a stuffy nose and severe constipation. Risk factors include family history and race (Northern European ancestry). Treatment includes antibiotics, mucus-thinning, bronchodilators and oral pancreatic enzymes.

Report Highlights

The Publisher's Pharmaceutical and Healthcare latest pipeline guide Cystic Fibrosis - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Cystic Fibrosis (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cystic Fibrosis (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Cystic Fibrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 5, 34, 18, 66 and 33 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical, Discovery and Unknown stages comprises 2, 1, 10, 9 and 1 molecules, respectively.

Cystic Fibrosis (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from The Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Cystic Fibrosis (Respiratory).
  • The pipeline guide reviews pipeline therapeutics for Cystic Fibrosis (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Cystic Fibrosis (Respiratory) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Cystic Fibrosis (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Cystic Fibrosis (Respiratory)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Cystic Fibrosis (Respiratory).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Cystic Fibrosis (Respiratory) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AbbVie Inc
  • Celtaxsys Inc
  • Evaxion Biotech ApS
  • Kither Biotech Srl
  • OrPro Therapeutics Inc
  • Sequoia Sciences Inc
  • MORE
Introduction
Cystic Fibrosis - Overview
Cystic Fibrosis - Therapeutics Development
Cystic Fibrosis - Therapeutics Assessment
Cystic Fibrosis - Companies Involved in Therapeutics Development
Cystic Fibrosis - Drug Profiles
Cystic Fibrosis - Dormant Projects
Cystic Fibrosis - Discontinued Products
Cystic Fibrosis - Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Cystic Fibrosis, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..5), H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Products under Development by Companies, H2 2019 (Contd..5), H2 2019
Products under Development by Companies, H2 2019 (Contd..6), H2 2019
Products under Development by Companies, H2 2019 (Contd..7), H2 2019
Products under Development by Companies, H2 2019 (Contd..8), H2 2019
Products under Development by Companies, H2 2019 (Contd..9), H2 2019
Products under Development by Universities/Institutes, H2 2019
Products under Development by Universities/Institutes, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..2), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..2), H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Cystic Fibrosis - Pipeline by 4D Molecular Therapeutics Inc, H2 2019
Cystic Fibrosis - Pipeline by AbbVie Inc, H2 2019
Cystic Fibrosis - Pipeline by Abeona Therapeutics Inc, H2 2019
Cystic Fibrosis - Pipeline by Agile Sciences Inc, H2 2019
Cystic Fibrosis - Pipeline by AGILeBiotics BV, H2 2019
Cystic Fibrosis - Pipeline by Alaxia SAS, H2 2019
Cystic Fibrosis - Pipeline by AlgiPharma AS, H2 2019
Cystic Fibrosis - Pipeline by Antabio SAS, H2 2019
Cystic Fibrosis - Pipeline by Arch Biopartners Inc, H2 2019
Cystic Fibrosis - Pipeline by Arcturus Therapeutics Ltd, H2 2019
Cystic Fibrosis - Pipeline by Armata Pharmaceuticals Inc, H2 2019
Cystic Fibrosis - Pipeline by Arrevus Inc, H2 2019
Cystic Fibrosis - Pipeline by Arrowhead Pharmaceuticals Inc, H2 2019
Cystic Fibrosis - Pipeline by AstraZeneca Plc, H2 2019
Cystic Fibrosis - Pipeline by Avidin Ltd, H2 2019
Cystic Fibrosis - Pipeline by BioAegis Therapeutics Inc, H2 2019
Cystic Fibrosis - Pipeline by Biolytx Pharmaceuticals Corp, H2 2019
Cystic Fibrosis - Pipeline by Boehringer Ingelheim International GmbH, H2 2019
Cystic Fibrosis - Pipeline by Breathe Easy Therapeutics Ltd, H2 2019
Cystic Fibrosis - Pipeline by Calista Therapeutics Inc, H2 2019
Cystic Fibrosis - Pipeline by Calithera Biosciences Inc, H2 2019
Cystic Fibrosis - Pipeline by Catabasis Pharmaceuticals Inc, H2 2019
Cystic Fibrosis - Pipeline by Celtaxsys Inc, H2 2019
Cystic Fibrosis - Pipeline by Chiesi Farmaceutici SpA, H2 2019
Cystic Fibrosis - Pipeline by Chrysalis Pharma SAS, H2 2019
Cystic Fibrosis - Pipeline by Cilian AG, H2 2019
Cystic Fibrosis - Pipeline by Corbus Pharmaceuticals Inc, H2 2019
Cystic Fibrosis - Pipeline by CRISPR Therapeutics AG, H2 2019
Cystic Fibrosis - Pipeline by CrowdOut Therapeutics, H2 2019
Cystic Fibrosis - Pipeline by Cyclacel Pharmaceuticals Inc, H2 2019
Cystic Fibrosis - Pipeline by Cyclenium Pharma Inc, H2 2019
Cystic Fibrosis - Pipeline by Daiichi Sankyo Co Ltd, H2 2019
Cystic Fibrosis - Pipeline by Destiny Pharma Plc, H2 2019
Cystic Fibrosis - Pipeline by DiscoveryBiomed Inc, H2 2019
Cystic Fibrosis - Pipeline by Druggability Technologies Holdings Ltd, H2 2019
Cystic Fibrosis - Pipeline by Editas Medicine Inc, H2 2019
Cystic Fibrosis - Pipeline by Eloxx Pharmaceuticals Inc, H2 2019
Cystic Fibrosis - Pipeline by EmphyCorp Inc, H2 2019
Cystic Fibrosis - Pipeline by EnBiotix Inc, H2 2019
Cystic Fibrosis - Pipeline by Enterprise Therapeutics Ltd, H2 2019
Cystic Fibrosis - Pipeline by Entrinsic Health Solutions, Inc., H2 2019
Cystic Fibrosis - Pipeline by Enzyvant Sciences Ltd, H2 2019
Cystic Fibrosis - Pipeline by Errant Gene Therapeutics LLC, H2 2019
Cystic Fibrosis - Pipeline by Evaxion Biotech ApS, H2 2019
Cystic Fibrosis - Pipeline by Evotec SE, H2 2019
Cystic Fibrosis - Pipeline by Exotect LLC, H2 2019
Cystic Fibrosis - Pipeline by Feldan Therapeutics Inc, H2 2019
Cystic Fibrosis - Pipeline by Galapagos NV, H2 2019
Cystic Fibrosis - Pipeline by Generation Bio Corp, H2 2019
Cystic Fibrosis - Pipeline by Genzyme Corp, H2 2019
Cystic Fibrosis - Pipeline by Grupo Praxis Pharmaceutical SA, H2 2019
Cystic Fibrosis - Pipeline by Helperby Therapeutics Group Ltd, H2 2019
Cystic Fibrosis - Pipeline by Horizon Therapeutics PLC, H2 2019
Cystic Fibrosis - Pipeline by Hypo-Stream Ltd, H2 2019
Cystic Fibrosis - Pipeline by Icagen Inc, H2 2019
Cystic Fibrosis - Pipeline by ID Pharma Co Ltd, H2 2019
Cystic Fibrosis - Pipeline by Idorsia Pharmaceutical Ltd, H2 2019
Cystic Fibrosis - Pipeline by Immun System IMS AB, H2 2019
Cystic Fibrosis - Pipeline by Invion Ltd, H2 2019
Cystic Fibrosis - Pipeline by Ionis Pharmaceuticals Inc, H2 2019
Cystic Fibrosis - Pipeline by Kamada Ltd, H2 2019
Cystic Fibrosis - Pipeline by Kither Biotech Srl, H2 2019
Cystic Fibrosis - Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2019
Cystic Fibrosis - Pipeline by Lakewood-Amedex Inc, H2 2019
Cystic Fibrosis - Pipeline by Lamellar Biomedical Ltd, H2 2019
Cystic Fibrosis - Pipeline by Laurent Pharmaceuticals Inc, H2 2019
Cystic Fibrosis - Pipeline by Lexicon Pharmaceuticals Inc, H2 2019
Cystic Fibrosis - Pipeline by MannKind Corp, H2 2019
Cystic Fibrosis - Pipeline by Mariposa Health Ltd, H2 2019
Cystic Fibrosis - Pipeline by Microbion Corp, H2 2019
Cystic Fibrosis - Pipeline by Mucokinetica Ltd, H2 2019
Cystic Fibrosis - Pipeline by Nanogenics Ltd, H2 2019
Cystic Fibrosis - Pipeline by Neupharma Srl, H2 2019
Cystic Fibrosis - Pipeline by New Amsterdam Sciences Inc, H2 2019
Cystic Fibrosis - Pipeline by Novabiotics Ltd, H2 2019
Cystic Fibrosis - Pipeline by Novartis AG, H2 2019
Cystic Fibrosis - Pipeline by Novoteris LLC, H2 2019
Cystic Fibrosis - Pipeline by Omnispirant Ltd, H2 2019
Cystic Fibrosis - Pipeline by Onspira Therapeutics Inc, H2 2019
Cystic Fibrosis - Pipeline by Orphomed Inc, H2 2019
Cystic Fibrosis - Pipeline by OrPro Therapeutics Inc, H2 2019
Cystic Fibrosis - Pipeline by Oryn Therapeutics, H2 2019
Cystic Fibrosis - Pipeline by Paranta Biosciences Ltd, H2 2019
Cystic Fibrosis - Pipeline by Pharmaero ApS, H2 2019
Cystic Fibrosis - Pipeline by Pharmaxis Ltd, H2 2019
Cystic Fibrosis - Pipeline by PhaseBio Pharmaceuticals Inc, H2 2019
Cystic Fibrosis - Pipeline by Polyphor AG, H2 2019
Cystic Fibrosis - Pipeline by Progenra Inc, H2 2019
Cystic Fibrosis - Pipeline by ProQR Therapeutics NV, H2 2019
Cystic Fibrosis - Pipeline by Protalix BioTherapeutics Inc, H2 2019
Cystic Fibrosis - Pipeline by Proteostasis Therapeutics Inc, H2 2019
Cystic Fibrosis - Pipeline by Pulmatrix Inc, H2 2019
Cystic Fibrosis - Pipeline by Rare Partners Srl, H2 2019
Cystic Fibrosis - Pipeline by Recode Therapeutics Inc, H2 2019
Cystic Fibrosis - Pipeline by Renovion Inc, H2 2019
Cystic Fibrosis - Pipeline by ReveraGen BioPharma Inc, H2 2019
Cystic Fibrosis - Pipeline by Riptide Bioscience Inc, H2 2019
Cystic Fibrosis - Pipeline by Santhera Pharmaceuticals Holding AG, H2 2019
Cystic Fibrosis - Pipeline by SciBac Inc, H2 2019
Cystic Fibrosis - Pipeline by Sequoia Sciences Inc, H2 2019
Cystic Fibrosis - Pipeline by Silurian Pharmaceuticals Inc, H2 2019
Cystic Fibrosis - Pipeline by SolAeroMed Inc, H2 2019
Cystic Fibrosis - Pipeline by Spirovant Sciences Inc, H2 2019
Cystic Fibrosis - Pipeline by Spyryx Biosciences Inc, H2 2019
Cystic Fibrosis - Pipeline by Synedgen Inc, H2 2019
Cystic Fibrosis - Pipeline by Synovo GmbH, H2 2019
Cystic Fibrosis - Pipeline by Synspira LLC, H2 2019
Cystic Fibrosis - Pipeline by Takeda Pharmaceutical Co Ltd, H2 2019
Cystic Fibrosis - Pipeline by TGV-Inhalonix Inc, H2 2019
Cystic Fibrosis - Pipeline by Translate Bio Inc, H2 2019
Cystic Fibrosis - Pipeline by Trucode Gene Repair Inc, H2 2019
Cystic Fibrosis - Pipeline by Vast Therapeutics Inc, H2 2019
Cystic Fibrosis - Pipeline by Vectura Group Plc, H2 2019
Cystic Fibrosis - Pipeline by Verona Pharma Plc, H2 2019
Cystic Fibrosis - Pipeline by Vertex Pharmaceuticals Inc, H2 2019
Cystic Fibrosis - Pipeline by Vironika LLC, H2 2019
Cystic Fibrosis - Pipeline by Zambon Co SpA, H2 2019
Cystic Fibrosis - Pipeline by Zata Pharmaceuticals Inc, H2 2019
Cystic Fibrosis - Dormant Projects, H2 2019
Cystic Fibrosis - Discontinued Products, H2 2019
Cystic Fibrosis - Discontinued Products, H2 2019 (Contd..1), H2 2019

List of Figures
Number of Products under Development for Cystic Fibrosis, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Number of Products by Top 10 Routes of Administration, H2 2019
Number of Products by Stage and Top 10 Routes of Administration, H2 2019
Number of Products by Top 10 Molecule Types, H2 2019
Number of Products by Stage and Top 10 Molecule Types, H2 2019
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • 4D Molecular Therapeutics Inc
  • AbbVie Inc
  • Abeona Therapeutics Inc
  • Agile Sciences Inc
  • AGILeBiotics BV
  • Alaxia SAS
  • AlgiPharma AS
  • Antabio SAS
  • Arch Biopartners Inc
  • Arcturus Therapeutics Ltd
  • Armata Pharmaceuticals Inc
  • Arrevus Inc
  • Arrowhead Pharmaceuticals Inc
  • AstraZeneca Plc
  • Avidin Ltd
  • BioAegis Therapeutics Inc
  • Biolytx Pharmaceuticals Corp
  • Boehringer Ingelheim International GmbH
  • Breathe Easy Therapeutics Ltd
  • Calista Therapeutics Inc
  • Calithera Biosciences Inc
  • Catabasis Pharmaceuticals Inc
  • Celtaxsys Inc
  • Chiesi Farmaceutici SpA
  • Chrysalis Pharma SAS
  • Cilian AG
  • Corbus Pharmaceuticals Inc
  • CRISPR Therapeutics AG
  • CrowdOut Therapeutics
  • Cyclacel Pharmaceuticals Inc
  • Cyclenium Pharma Inc
  • Daiichi Sankyo Co Ltd
  • Destiny Pharma Plc
  • DiscoveryBiomed Inc
  • Druggability Technologies Holdings Ltd
  • Editas Medicine Inc
  • Eloxx Pharmaceuticals Inc
  • EmphyCorp Inc
  • EnBiotix Inc
  • Enterprise Therapeutics Ltd
  • Entrinsic Health Solutions, Inc.
  • Enzyvant Sciences Ltd
  • Errant Gene Therapeutics LLC
  • Evaxion Biotech ApS
  • Evotec SE
  • Exotect LLC
  • Feldan Therapeutics Inc
  • Galapagos NV
  • Generation Bio Corp
  • Genzyme Corp
  • Grupo Praxis Pharmaceutical SA
  • Helperby Therapeutics Group Ltd
  • Horizon Therapeutics PLC
  • Hypo-Stream Ltd
  • Icagen Inc
  • ID Pharma Co Ltd
  • Idorsia Pharmaceutical Ltd
  • Immun System IMS AB
  • Invion Ltd
  • Ionis Pharmaceuticals Inc
  • Kamada Ltd
  • Kither Biotech Srl
  • Kyorin Pharmaceutical Co Ltd
  • Lakewood-Amedex Inc
  • Lamellar Biomedical Ltd
  • Laurent Pharmaceuticals Inc
  • Lexicon Pharmaceuticals Inc
  • MannKind Corp
  • Mariposa Health Ltd
  • Microbion Corp
  • Mucokinetica Ltd
  • Nanogenics Ltd
  • Neupharma Srl
  • New Amsterdam Sciences Inc
  • Novabiotics Ltd
  • Novartis AG
  • Novoteris LLC
  • Omnispirant Ltd
  • Onspira Therapeutics Inc
  • Orphomed Inc
  • OrPro Therapeutics Inc
  • Oryn Therapeutics
  • Paranta Biosciences Ltd
  • Pharmaero ApS
  • Pharmaxis Ltd
  • PhaseBio Pharmaceuticals Inc
  • Polyphor AG
  • Progenra Inc
  • ProQR Therapeutics NV
  • Protalix BioTherapeutics Inc
  • Proteostasis Therapeutics Inc
  • Pulmatrix Inc
  • Rare Partners Srl
  • Recode Therapeutics Inc
  • Renovion Inc
  • ReveraGen BioPharma Inc
  • Riptide Bioscience Inc
  • Santhera Pharmaceuticals Holding AG
  • SciBac Inc
  • Sequoia Sciences Inc
  • Silurian Pharmaceuticals Inc
  • SolAeroMed Inc
  • Spirovant Sciences Inc
  • Spyryx Biosciences Inc
  • Synedgen Inc
  • Synovo GmbH
  • Synspira LLC
  • Takeda Pharmaceutical Co Ltd
  • TGV-Inhalonix Inc
  • Translate Bio Inc
  • Trucode Gene Repair Inc
  • Vast Therapeutics Inc
  • Vectura Group Plc
  • Verona Pharma Plc
  • Vertex Pharmaceuticals Inc
  • Vironika LLC
  • Zambon Co SpA
  • Zata Pharmaceuticals Inc
Note: Product cover images may vary from those shown
Adroll
adroll